Bavarian Nordic expects revenue setback in 2022

Key 2021 figures from Bavarian Nordic’s annual report are in line with projections, but scrape the bottom of previous estimations. 2022 will be a year of investments for the biotech company, which is why an operating deficit is already being forecasted.

Photo: Bavarian Nordic / PR

Biotech company Bavarian Nordic almost made a comeback in 2021 – but not quite.

According to Bavarian Nordic’s annual report on Friday, the company realized a revenue of DKK 1,895m (USD 280.5m), but an operating deficit (EBIT) of DKK 313.5m (USD 46.4m).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs